Le Lézard
Classified in: Health
Subject: TRI

Soin Neuroscience commences a clinical case series with Nuvectra's Algovita spinal cord stimulator for back pain

DAYTON, Ohio, March 8, 2018 /PRNewswire/ -- Soin Neuroscience, a biotech company based in Dayton, OH, has received IRB (institutional review board) approval to commence a clinical case series to study spinal cord stimulator algorithms in patients who suffer from back pain. Dr Amol Soin, a pain management physician and CEO of Soin Neuroscience, will be running the study in Dayton, OH. "I look forward to using Nuvectra's Algovita, and its powerful spinal cord stimulator system to treat patients with back pain. We will be trialing waveforms that are unique to Nuvectra's system. This is a small study that I hope will allow us to run additional larger studies. I think we can help a lot of people with back pain."

Dr. Amol Soin, founder and CEO of Soin Neuroscience, and pain management physician.

The study will be run in Dayton, OH. Patients who suffer from debilitating back may be considered good candidates for the study.

About Soin Neuroscience:

Soin Neuroscience (SNI) is a pharmaceutical startup company based in Dayton, OH that specializes in treating pain and other neurological conditions. Its lead compound, TV1001SR, is entering late stage trials to treat systemic sclerosis and diabetic peripheral neuropathy. SNI also has multiple other compounds in development including a way to restore functional motor and cognitive function after ischemic stroke, a method to treat intensive care unit myopathy, and is working on an option to treat Huntington's disease. The company was founded by Dr. Amol Soin who is also an inventor on most of the core technologies that are being developed. He can be reached at drsoin@soinneuroscience.com.

 (PRNewsfoto/Soin Neuroscience)

SOURCE Soin Neuroscience

These press releases may also interest you

at 02:00
Brammer Bio ("Brammer"), a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies, announces recent leadership appointments to support the...

at 01:00
WASHINGTON, March 20, 2018 /PRNewswire-PRWeb/ -- The American Academy of Nursing released its policy brief urging nurses to have an increased role in enhancing health literacy for patient populations. Health literacy is a precursor to health, and...

at 00:01
For the second consecutive year, total payments to care for individuals living with Alzheimer's or other dementias are projected to surpass a quarter of a trillion dollars ($277 billion), which includes an increase of nearly $20 billion over last...

at 00:01
Case Western Reserve University School of Medicine has been named the #1 medical school in Ohio, according to the annual ranking of graduate schools released today by U.S. News & World Report. The school was also ranked 25th of all research-oriented...

19 mar 2018
Helix BioPharma Corp. ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal quarter ended January 31,...

19 mar 2018
Tevosol, Inc. ("Tevosol" or the "Company") today announces: (i) changes to its senior management team; (ii) additions to the Company's Advisory Board; and (iii) the beginning of the Company's first human Investigator Lead Trial ("ILT").  These...

News published on 8 march 2018 at 18:18 and distributed by: